Patrick Robert Griffin

Patrick Robert Griffin

Auto-generated profile, based on publicly available information

Patrick Robert Griffin

The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2011 in Nature
Verified
Journal Article
Open access
PDF file
JCJang Hyun Choi
Jang Hyun Choi
ABAlex Banks
Alex Banks
TKTheodore M. Kamenecka
Theodore M. Kamenecka
SBScott A. Busby
Scott A. Busby
MCMichael J. Chalmers
Michael J. Chalmers
PGPatrick R. Griffin
Patrick R. Griffin
The nuclear receptor PPARγ is the target of thiazolidinedione antidiabetics including rosiglitazone and pioglitazone. These full PPARγ agonists are effective and well tolerated in most patients, but cause fluid retention and weight gain in a minority. In this proof-of-concept study, Choi et al. show the development of specific PPARγ ligands that retain antidiabetic activity through blockade of Cdk5-mediated PPARγ phosphorylation, but that are not full PPARγ agonists. In mouse models, these ligands do not cause the side effects sometimes associated with full PPARγ agonists. PPARγ is the functioning receptor for the thiazolidinedione (TZD) class of antidiabetes drugs including rosiglitazone and pioglitazone1. These drugs are full classical agonists for this nuclear receptor, but recent data have shown that many PPARγ-based drugs have a separate biochemical activity, blocking the obesity-linked phosphorylation of PPARγ by Cdk5 (ref. 2). Here we describe novel synthetic compounds that have a unique mode of binding to PPARγ, completely lack classical transcriptional agonism and block the Cdk5-mediated phosphorylation in cultured adipocytes and in insulin-resistant mice. Moreover, one such compound, SR1664, has potent antidiabetic activity while not causing the fluid retention and weight gain that are serious side effects of many of the PPARγ drugs. Unlike TZDs, SR1664 also does not interfere with bone formation in culture. These data illustrate that new classes of antidiabetes drugs can be developed by specifically targeting the Cdk5-mediated phosphorylation of PPARγ.

2 February 2016 in eLife
Verified
Journal Article
Open access
Sean FanningSean Fanning
Sean Fanning
CMChristopher G Mayne
Christopher G Mayne
VDVenkatasubramanian Dharmarajan
Venkatasubramanian Dharmarajan
KCKathryn E Carlson
Kathryn E Carlson
TMTeresa A Martin
Teresa A Martin
GGGeoffrey Greene
Geoffrey Greene
Somatic mutations in the estrogen receptor alpha (ERα) gene (ESR1), especially Y537S and D538G, have been linked to acquired resistance to endocrine therapies. Cell-based studies demonstrated that these mutants confer ERα constitutive activity and antiestrogen resistance and suggest that ligand-binding domain dysfunction leads to endocrine therapy resistance. Here, we integrate biophysical and structural biology data to reveal how these mutations lead to a constitutively active and antiestrogen-resistant ERα. We show that these mutant ERs recruit coactivator in the absence of hormone while their affinities for estrogen agonist (estradiol) and antagonist (4-hydroxytamoxifen) are reduced. Further, they confer antiestrogen resistance by altering the conformational dynamics of the loop connecting Helix 11 and Helix 12 in the ligand-binding domain of ERα, which leads to a stabilized agonist state and an altered antagonist state that resists inhibition.

13 June 2012 in Journal of the American Society for Mass Spectrometry
Verified
Journal Article
Closed access
PDF file
BPBruce D. Pascal
Bruce D. Pascal
SWScooter Willis
Scooter Willis
JLJanelle L. Lauer
Janelle L. Lauer
RLRachelle R. Landgraf
Rachelle R. Landgraf
GWGraham M. West
Graham M. West
PGPatrick R. Griffin
Patrick R. Griffin

16 October 2020 in Science
Verified
Journal Article
Closed access
SBStephanie M. Bester
Stephanie M. Bester
GWGuochao Wei
Guochao Wei
HZHaiyan Zhao
Haiyan Zhao
DADaniel Adu-Ampratwum
Daniel Adu-Ampratwum
NINaseer Iqbal
Naseer Iqbal
MKMamuka Kvaratskhelia
Mamuka Kvaratskhelia
Attacking HIV by stabilizing its capsid: Current HIV treatments require drugs that must be taken daily, and care would be improved with an effective drug that is long-acting. GS-6207 (Lenacapavir) is a drug developed by Gilead Sciences that shows potential for a 6-month dosing interval and is in phase 2/3 clinical trials. Bester et al. describe structural and biophysical studies that provide a basis for the potent antiviral activity of GS-6207. The HIV capsid is cone shaped, and GS-6207 binds two neighboring capsid subunits and stabilizes the curved capsid. GS-6207 also interferes with capsid binding of cofactors that play a role in viral infection. This insight into GS-6207 activity provides a platform for the rational development of improved long-acting therapies. Science , this issue p. 360

1 February 2011 in Expert Review of Proteomics
Verified
Journal Article
Closed access
MCMichael J Chalmers
Michael J Chalmers
SBScott A Busby
Scott A Busby
BPBruce D Pascal
Bruce D Pascal
GWGraham M West
Graham M West
PGPatrick R Griffin
Patrick R Griffin
(2011). Differential hydrogen/deuterium exchange mass spectrometry analysis of protein–ligand interactions. Expert Review of Proteomics: Vol. 8, No. 1, pp. 43-59.

1 February 2010 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
NKNaresh Kumar
Naresh Kumar
LSLaura A. Solt
Laura A. Solt
JCJuliana J. Conkright
Juliana J. Conkright
YWYongjun Wang
Yongjun Wang
MIMonica A. Istrate
Monica A. Istrate
PGPatrick R. Griffin
Patrick R. Griffin
Retinoic acid receptor-related orphan receptors (RORs) regulate a variety of physiological processes including hepatic gluconeogenesis, lipid metabolism, circadian rhythm, and immune function. Here we present the first high-affinity synthetic ligand for both RORα and RORγ. In a screen against all 48 human nuclear receptors, the benzenesulfonamide liver X receptor (LXR) agonist N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide (T0901317) inhibited transactivation activity of RORα and RORγ but not RORβ. T0901317 was found to directly bind to RORα and RORγ with high affinity (Ki = 132 and 51 nM, respectively), resulting in the modulation of the receptor9s ability to interact with transcriptional cofactor proteins. T0901317 repressed RORα/γ-dependent transactivation of ROR-responsive reporter genes and in HepG2 cells reduced recruitment of steroid receptor coactivator-2 by RORα at an endogenous ROR target gene (G6Pase). Using small interference RNA, we demonstrate that repression of the gluconeogenic enzyme glucose-6-phosphatase in HepG2 cells by T0901317 is ROR-dependent and is not due to the compound9s LXR activity. In summary, T0901317 represents a novel chemical probe to examine RORα/γ function and an excellent starting point for the development of ROR selective modulators. More importantly, our results demonstrate that small molecules can be used to target the RORs for therapeutic intervention in metabolic and immune disorders.